Dr. Reddy's Laboratories Launches Vigabatrin Tablets, USP in the US Market
3 February 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril (vigabatrin) Tablets, USP, approved by the US Food and Drug Administration (USFDA), the company said.

The Sabril brand and generic had US sales of approximately USD 141m MAT for the most recent twelve months ending in December 2020 according to IMS Health.

Dr. Reddy's Vigabatrin Tablets, USP are available in 500 mg tablets in a bottle count size of 100.
Please see for full prescribing information including boxed warning.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include USA, India, Russia and CIS countries, and Europe.